Latest Conference Articles

The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.

A consistent progression-free and overall survival benefit was reported among patients with hormone receptor-positive, HER2-negative advanced breast cancer, regardless of age.

Patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer reported positive outcomes following treatment with capivasertib plus fulvestrant.

A phase 3 trial based out of India suggests that olanzapine may be useful in reducing chemotherapy-induced nausea and vomiting.

Incorporating frailty screenings into preexisting workflows may be an effective way to provide more holistic care to patients with head and neck cancer.

Investigators reflect on the Oncology Care Model and its implications.

The median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.

The duration of response was 39.2 months among patients with 1 metastatic site treated in the combination arm vs 29.5 months for patients given sunitinib.

Patients who received amivantamab plus lazertinib and chemotherapy achieved a median progression-free survival of 8.3 months.

The median progression-free survival was 23.7 months with the combination vs 16.6 months with osimertinib alone.

The median radiologic progression-free survival was 12.02 months in the 177Lu-PSMA-617 group vs 5.59 months in the androgen receptor pathway inhibitor change group.

Datopotamab deruxtecan improved progression-free survival in select subsets of patients with advanced or metastatic non–small-cell lung cancer.

Patients with metastatic hormone receptor-positive breast cancer treated with datopotamab deruxtecan experienced a statistically significant and clinically meaningful improvement in progression-free survival.

Sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer.

The 12-month overall survival rates were 48.7% and 35.3% with tisotumab vedotin and chemotherapy, respectively, among patients with recurrent or metastatic cervical cancer.

Patients who received induction chemotherapy prior to chemoradiation had a 35% reduced risk of progression or death.

Nivolumab plus gemcitabine-cisplatin improved overall and progression-free survival in unresectable or metastatic urothelial carcinoma.

For the first time, a new therapeutic regimen outperformed chemotherapy in improving overall survival in frontline urothelial cancer.

Durvalumab plus first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib, emerges as a potentially effective combination for patients with limited treatment options.

Amivantamab plus chemotherapy nearly doubled the progression-free survival in patients with EGFR Exon 20-mutated non–small-cell lung cancer.

In the intention-to-treat population, the median progression-free survival was 24.8 months with selpercatinib vs 11.2 months.

The median progression-free survival was not reached with selpercatinib vs 16.8 months with other kinase inhibitors.

Adjuvant alectinib significantly improved disease-free survival in patients with ALK-positive, early-stage, non–small-cell lung cancer.

Treatment with neoadjuvant nivolumab, followed by adjuvant nivolumab after surgery, led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.

Tarlatamab induced a 40% objective response rate among patients with pretreated small cell lung cancer—including many patients who had already received 3 lines of therapy.

Fixed-duration venetoclax plus rituximab continued to outperform bendamustine plus rituximab in the phase 3 MURANO trial.

Older patients with kidney cancer experienced “exceptional” disease control with stereotactic ablative radiotherapy—which is noninvasive and occurs in the outpatient setting.

Clinical navigators helped increase the rate of genomic testing referrals among Black patients with prostate cancer—a group that faces significant health disparities in the care system.

Reduced-dose or partial-breast radiotherapy showed comparable safety and efficacy outcomes compared with whole-breast radiotherapy.

Cervical cancer survivors who regularly engage in sex or use vaginal dilators report lower levels of vaginal shortening.